ATP2C1 blockers(ATPase secretory pathway Ca2+ transporting 1 blockers), GABRA1 agonists(gamma-aminobutyric acid type A receptor subunit alpha1 agonists), GLRA1 agonists(glycine receptor alpha 1 agonists)

Therapeutic Areas

Other DiseasesNeoplasmsNervous System Diseases+ [2]

Active Indication

AnesthesiaBreast CancerReperfusion Injury+ [1]

Inactive Indication-

Originator Organization

AbbVie, Inc.

Active Organization

Stony Brook University HospitalChina Medical University Hospital

AbbVie, Inc.

+ [2]

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (20 Apr 1990),

Anesthesia

Regulation-

Structure

Molecular FormulaC4H3F7O

InChIKeyDFEYYRMXOJXZRJ-UHFFFAOYSA-N

CAS Registry28523-86-6

824

Clinical Trials associated with Sevoflurane

NCT03643367 / Not yet recruitingPhase 2IIT

Sevoflurane Sedation: A Potentially Promising Immunomodulation in Patients With Septic Shock

Recent in vivo studies from others as well as the investigators group demonstrated that volatile anesthetics immunomodulate sepsis and improve outcome. Also, several clinical trials have convincingly shown that application of a volatile anesthetic provides protection in patients undergoing major surgery.
Patients with sepsis are intubated and ventilated and therefore need sedation. So far, most ICU centers use intravenously applied sedatives in these patients. In the proposed study, we will switch sedation from an intravenous to a volatile anesthetic for a short period of time to explore if sepsis markers improve within the following 120 hours upon sevoflurane conditioning.

Start Date01 Jan 2025

Sponsor / Collaborator

University of Zurich

[+2]

NCT06560268 / Not yet recruitingPhase 4IIT

Effects of Different Fresh Gas Flows on Emergence Agitation and Anesthetic Agent Consumption in Children Undergoing Strabismus Surgery

Emergence agitation (EA) involves restlessness, disorientation, excitation, non-purposeful movement, inconsolability, thrashing, and incoherence during early recovery from general anesthesia. Sevoflurane and desflurane have increased the incidence of EA in children. A proposed explanation for this is that sevoflurane and desflurane cause differential recovery rates in brain function, due to differences in clearance of inhalational anesthetics from the central nervous system; whereas audition and locomotion recover first, cognitive function recovers later, resulting in EA. Low-flow anaesthesia (LFA) occurs when the fresh gas flow (FGF) is significantly lower than the patient's minute volume. In a low-flow system, the recirculated fraction should amount to at least 50% after carbon dioxide (CO2) absorption.In LFA using minimal FGF (250-500 mL/min), if the vaporizer is turned off 10-15 minutes before the end of the operation and the FGF is not changed, the inhaled anesthetic agent concentration gradually and slowly decreases to zero and the inhaled agent consumption decreases even more. In a study conducted on infants undergoing cleft lip-palate surgery, it was shown that the incidence of postoperative agitation were statistically lower in infants who administered 0.5 L/min FGF.
Strabismus surgery is one of the most frequently performed ophthalmologic operations in children and is associated with moderate postoperative pain and a high incidence of EA (40-86%). The incidence of EA after strabismus surgery is high, especially due to visual disturbances; however, the pathogenesis of this condition remains unclear. In our study, the effects of different FGFs administered in children undergoing strabismus surgery on EA and anesthetic agent consumption will be investigated.

Start Date04 Nov 2024

Sponsor / Collaborator

Cukurova University

NCT06624592 / Not yet recruitingPhase 3IIT

Sevoflurane/Dexmedetomidine vs. Isoflurane and Their Effects on Pediatric Emergence Delirium

The purpose of this study is to measure the incidences of pediatric emergence delirium between the group receiving Isoflurane and the group receiving Sevoflurane plus intravenous push dexmedetomidine.

Start Date01 Nov 2024

Sponsor / Collaborator

Mayo Clinic

100 Clinical Results associated with Sevoflurane

100 Translational Medicine associated with Sevoflurane

100 Patents (Medical) associated with Sevoflurane

10,921

Literatures (Medical) associated with Sevoflurane

01 Mar 2025·Medical Gas Research

Research progress in the clinical application of inhaled anesthetic sevoflurane

Review

Author: Wang, Sheng ; Wu, Hao ; Tang, Chao-Liang ; Dai, Fei-Biao

Sevoflurane has been widely used in clinical anesthesia as an inhalation anesthetic. With the development of medicine, there have been several new applications in recent years, such as daytime surgery, labor analgesia, and combined nerve block for some surgeries. Moreover, as research progresses, it has been found that it not only has potential organ protection effects but can also be used to treat severe asthma and relieve the tracheal spasm state. In addition, local administration can effectively treat vascular ulcers. We briefly review the organ protective effect of sevoflurane, its application in dental treatment, asthma treatment, vascular ulcer treatment and some new progress in clinical application.

01 Mar 2025·Medical Gas Research

Anesthesia and its environmental impact: approaches to minimize exposure to anesthetic gases and reduce waste

Review

Author: Siddiqui, Khalid Maudood ; Yousuf, Muhammad Saad ; Ahmed, Syed Shabbir ; Ullah, Hameed ; Latif, Asad ; Samad, Khalid

In today’s era of modern healthcare, the intersection between medical practices and environmental responsibility has gained significant attention. One such area of focus is the practice of anesthesia, which plays a crucial role in various surgical procedures. Anesthetics such as nitrous oxide and volatile halogenated ethers (desflurane, isoflurane, sevoflurane) are examples of medical gases that are strong greenhouse gases that contribute to global warming. During medical procedures, most of these anesthetic agents are released into the atmosphere, which exacerbates their influence on the environment. Also anesthesia delivery systems have traditionally utilized high flow rates of gases, leading to not only excessive consumption but also a considerable environmental impact in terms of greenhouse gas emissions. However, the emergence of low-flow anesthesia (LFA) presents a promising solution for achieving emission reduction and cost savings, thereby aligning healthcare practices with sustainability goals. Understanding LFA involves the administration of anesthetic gases to patients at reduced flow rates compared to conventional high-flow methods. This practice requires precision in gas delivery, often incorporating advanced monitoring and control systems. By optimizing gas flow to match the patient’s requirements, LFA minimizes wastage and excessive gas release into the environment, subsequently curbing the carbon footprint associated with healthcare operations. Decreasing volatile anesthetic delivery provides safe and effective strategies for anesthesia providers to decrease costs and reduce environmental pollution. Current literature support in favor of LFA represents an area of cost containment and an opportunity to lessen the environmental impact of anesthesia. This article will cover the concept of LFA, the distinctions between low flow and minimal flow, and the potential advantages of LFA, such as those related to patient safety, the environment, and the economy.

01 Jan 2025·RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY

The activity of suprahyoid muscles during sevoflurane-induced gasping in mice

Article

Author: Nishino, Takashi ; Jin, Hisayo ; Isono, Shiroh ; Hashida, Mayumi ; Taiji, Saki

Sevoflurane-induced gasping in mice involves an enormous increase in inspiratory effort, mandibular movement, and a marked decrease in respiratory frequency (fR). We examined differences in breathing patterns and electromyogram activity (EMG_SH) of the suprahyoid muscles (SHMs) during eupnea under 3.2% (1 MAC: minimum alveolar concentration) sevoflurane inhalation and sevoflurane-induced gasping under 6.5% (2 MAC) sevoflurane inhalation in eight spontaneously breathing, tracheally intubated, adult mice. We found that the phasic EMG_SH is obtained only during inspiration in eupnea and gasping and that integrated EMG_SH increases more, as a percent of baseline (% baseline) than tidal volume (V_T) during gasping (median [interquartile range]; integrated EMG_SH: 720 [425-1965] vs. V_T: 300 [238-373], P<0.05). We also found that the onset of EMG_SH precedes the start of airflow while maintaining a bell-shaped EMG_SH contour, which characterizes the EMG of upper airway dilator (UAD) muscles during eupnea and gasping. Vigorous respiratory-related mandibular movements were never observed during eupnea but were observed in seven of 8 mice during sevoflurane-induced gasping. Our observations indicate that SHMs act as a preferentially activating UAD muscle, contributing to the development of mandibular respiratory movements.

News (Medical) associated with Sevoflurane

02 Apr 2024

·www.prnewswire.com

Mars Veterinary Health pilots industry-leading anaesthetic gas capture technology to reduce carbon emissions

World's leading provider of veterinary care will be first to introduce innovative in-clinic solution to support sustainability goals BIRMINGHAM, England, April 3, 2024 /PRNewswire/ -- Mars Veterinary Health, through its UK veterinary group Linnaeus and in partnership with Waltham Petcare Science Institute, today announced a first-of-its-kind partnership with SageTech Veterinary to pilot an innovative anaesthetic gas capture solution to help prevent harmful greenhouse gases from entering the atmosphere. During a typical anaesthetic procedure, less than five percent of the volatile anaesthetic agent delivered to a patient is absorbed and metabolised, leaving approximately 95 percent it to be exhaled. Continue Reading Mars Veterinary Health pilots industry-leading anaesthetic gas capture technology to reduce carbon emissions SageTech's trusted gas-capture technology—which is currently used in human healthcare—works by capturing the waste anaesthetic agent breathed out during an operation by safely adsorbing it into a specially developed reusable capture canister. These waste anaesthetic agents can then be extracted from the filter, avoiding current routes for disposal of volatile anaesthetic agents of incineration or release into the atmosphere. "As a leading provider of veterinary care, we have a responsibility to take climate action at scale and lead the way toward more sustainable practices," said Ellie West, RCVS and EBVS® European Specialist in Veterinary Anaesthesia and Analgesia, and Linnaeus Environmental Sustainability Lead. "Our innovative collaboration should help us take a significant step forward in our sustainability journey, aimed at contributing to a better future for the planet—and the people and pets who depend on it." A veterinary-industry first, Mars Veterinary Health's one-year pilot will start with 10 Linnaeus primary care and referral veterinary practices in the UK with the aim of reducing anaesthesia-related carbon emissions resulting from release or disposal of these agents and determining the efficiency of capture in its clinics, ultimately supporting its goal of reducing climate-change impacts. Mars Veterinary Health aims to use these learnings to explore the potential application of this technology across other parts of its business in the years to come. "At SageTech Veterinary, we are excited to share our developed technology and work alongside Mars Veterinary Health to significantly reduce the carbon footprint associated with the direct release of waste volatile anaesthetic agents to the environment," said Iain Menneer, CEO of SageTech Medical. "It has been wonderful to work with the Linnaeus and Waltham teams, and we are confident this pilot project will demonstrate to the veterinary profession how such collaborations can be a collective force for good." This industry-first pilot in sustainable veterinary care is consistent with Mars, Incorporated's Net Zero Roadmap, a detailed action plan for achieving net zero greenhouse gas emissions by 2050, as well as details on the company's progress and history of working on climate action. Details about Mars, Incorporated's wider sustainability—including climate—work can be found in its Sustainable in a Generation Scorecard. About Mars Veterinary Health Mars Veterinary Health is a global division of Mars Petcare dedicated to delivering high-quality pet healthcare to further its collective Purpose: A BETTER WORLD FOR PETS™. Mars Veterinary Health's 70,000 Associates across 3,000 global veterinary clinics put pets, people, and the planet first. The Mars Veterinary Health family includes Associates at AniCura, Banfield, BluePearl, Creature Comforts, Gentle Oak, Hillside, Linnaeus, Mount Pleasant, Tai Wai, VCA, VES, and VSH who demonstrate compassion and expertise while enabling 35 million pet visits each year. Learn more at marsveterinary.com. About Linnaeus Part of Mars Veterinary Health, Linnaeus is a highly respected community of more than 50 primary care and 17 referral veterinary practices based in the UK. Linnaeus employs over 6,000 pet-loving Associates with some of the country's finest vet and nursing teams who together are committed to excellence and delivering high-quality care to patients. Learn more at linnaeusgroup.co.uk. About Mars Science & Diagnostics Mars Science & Diagnostics is a division of Mars Petcare, a diverse business dedicated to one purpose: A BETTER WORLD FOR PETS™. Science & Diagnostics brings together the power of leading pet health science with expertise across diagnostics, data, and technology to improve outcomes in pet health. Antech, our global veterinary diagnostics business, spans in-house diagnostic laboratory instruments and consumables, including rapid assay diagnostic products and digital cytology services; local and cloud-based data services; practice information management software; reference laboratories; veterinary imaging and technology; education; and telemedicine with board-certified specialist support services. Our at-home diagnostics offering includes Wisdom Panel, the world's most accurate pet DNA test. For 60 years, our Waltham Petcare Science Institute has been advancing science to better understand pet health. About SageTech Veterinary The manufacture of virgin anaesthetic agents and their release as waste volatile gases is highly damaging to the environment and contributes significantly to the total carbon footprint of healthcare. SageTech Veterinary is part of SageTech Medical, a medical device and pharmaceutical company focused on the research, design, manufacture, and distribution of technologies for the capture and recycling of waste volatile anaesthetic agents in human and animal healthcare. Their unique circular economy solution safely captures volatile anaesthetic agents (sevoflurane, isoflurane, desflurane) through actively controlled adsorption onto a reusable capture canister. Learn more at sagetechveterinary.com. Photo - SOURCE Mars PetCare

12 Jan 2023

·www.medicalplasticsnews.com

Diamedica to showcase anaesthesia and respiratory solutions at Arab Health

UK manufacturer Diamedica will be showcasing how their portable systems can enable safe anaesthesia and respiratory support in limited resource settings at Arab Health 2023. Joining the ABHI UK Pavilion, the company will be showcasing its Glostavent DPA03 portable anaesthesia machine and the Diamedica Portable CPAP, a small, hands-free, neonatal CPAP device, designed to function in some of the world’s most challenging environments. Manufactured in the UK, the portable Glostavent DPA03 does not require electrical or battery power and is designed to function anywhere, from the field or working to an outreach hospital or rural clinic. Its two vaporisers make it suitable for use with Halothane, Isoflurane or Sevoflurane so users can maximise resources. Lightweight and assembled in two minutes, the system is contained in a tough Peli case, making it safe and easy to transport to help save lives. The system can be optionally supplied with a vital signs monitor, improving the safety and efficacy of anaesthesia provision to the patient. The portable system is designed to provide excellent economy of oxygen use, with just two litres per minute of oxygen providing the average patient with 50% FiO2. In low-resource settings, access to CPAP can be scarce. To meet this need, Diamedica have created the Diamedica Portable CPAP, a low cost, and portable CPAP device designed to support neonates and infants with respiratory distress syndrome. Manufactured with simplicity in mind, the system provides filtered room air through a patient cannula interface. It provides a compact and effective respiratory device for use in a range of settings including transport internally in the hospital or externally to another facility. The device can also be used when the number of patients in need of CPAP therapy exceeds the number of standalone CPAP machines available or when electricity or compressed gas supply is not readily available. Diamedica’s award-winning technology is already in use in more than 80 countries around the world. Charlotte Green, head of sales and marketing at Diamedica, said: “Arab Health sees thousands of industry players congregate in Dubai for four days of business and knowledge sharing, the perfect location to showcase our latest innovations. We look forward meeting key stakeholders and potential distributors to discuss our sustainable and innovative medical device solutions and demonstrate how our anaesthesia and respiratory solutions are specifically designed to perform to full capability in some of the most challenging environments around the world.” Diamedica’s product range extends from full hospital anaesthetic machines, oxygen concentrator driven CPAP, oxygen reservoir filling system, to portable anaesthesia and ventilation for field hospitals, outreach missions, conflict and humanitarian situations. All designed to bespoke specifications to suit low-resource settings. Recognised as an expert in the field, the company works hand-in-hand with in-country partners to provide training, education and distribution to equip their customers with the knowledge and resources they need. The Arab Health Exhibition & Congress is taking place from 30 January – 2 February 2023 at the Dubai Convention and Exhibition Centre. Throughout the exhibition, Diamedica will be located on the ABHI UK Pavilion – Stand H2.D14.

02 Dec 2022

·www.businesswire.com

Global Inhalation Anesthetics Market to Reach $1.5 Billion by 2027 at a CAGR of 3.7% - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Inhalation Anesthetics: Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. Global Inhalation Anesthetics Market to Reach $1.5 Billion by 2027 In the changed post COVID-19 business landscape, the global market for Inhalation Anesthetics estimated at US$1.2 Billion in the year 2020, is projected to reach a revised size of US$1.5 Billion by 2027, growing at a CAGR of 3.7% over the analysis period 2020-2027. Sevoflurane, one of the segments analyzed in the report, is projected to record a 3.6% CAGR and reach US$906.9 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Desflurane segment is readjusted to a revised 4.3% CAGR for the next 7-year period. The U.S. Market is Estimated at $349 Million, While China is Forecast to Grow at 3.4% CAGR The Inhalation Anesthetics market in the U.S. is estimated at US$349 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$273.6 Million by the year 2027 trailing a CAGR of 3.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.5% and 3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR. Nitrous Oxide Segment to Record 3.4% CAGR In the global Nitrous Oxide segment, USA, Canada, Japan, China and Europe will drive the 3.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$138 Million in the year 2020 will reach a projected size of US$175 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Select Competitors (Total 41 Featured) - 058 LatchGas Abbott Laboratories, Inc. AbbVie, Inc. Accutron Baxter International, Inc. Chester County Family Dentistry Discover Dental Eisai Co., Ltd. Fox Family Dentistry Fresenius Kabi AG Key Topics Covered: I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Inhalation Anesthetics - Global Key Competitors Percentage Market Share in 2022 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE III. MARKET ANALYSIS IV. COMPETITION Companies Mentioned 058 LatchGas Abbott Laboratories, Inc. AbbVie, Inc. Accutron Baxter International, Inc. Chester County Family Dentistry Discover Dental Eisai Co., Ltd. Fox Family Dentistry Fresenius Kabi AG For more information about this report visit https://www.researchandmarkets.com/r/h9qiji

100 Deals associated with Sevoflurane

External Link

KEGG	Wiki	ATC	Drug Bank
D00547	Sevoflurane	N01AB08	DB01236

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anesthesia	JP	Maruishi Pharmaceutical Co., Ltd.	20 Apr 1990

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Breast Cancer	Preclinical	US	Stony Brook University Hospital	02 Jun 2022
Reperfusion Injury	Preclinical	CN	Xinjiang Medical University	01 Jan 2016
Alzheimer Disease	Preclinical	TW	China Medical University Hospital	01 Jul 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02697448 (CTgov)	Not Applicable	Atrial Fibrillation	135	propofol (Propofol)	hplzxtjecm(cosnmldypy) = rjzeowrdev seufksvvxo (wyidncltya, ljpkatgzma - tisoizwlbt) View more	-	20 Aug 2024
				sevoflurane (Sevoflurane)	hplzxtjecm(cosnmldypy) = orjwdaunhp seufksvvxo (wyidncltya, euoskaqhnt - upqyzbuerl) View more
NCT02053766 (CTgov)	Not Applicable	Mitochondrial Diseases	19	Dexmedetomidine (Dexmedetomidine (Precedex®))	rrqovbvxve(qtanowbxnq) = uvcsapzkyj gchledzchm (kxojkgucxh, bsduoiepko - bepftpadkt) View more	-	17 Jul 2024
				Propofol (Propofol)	rrqovbvxve(qtanowbxnq) = ckatziqhje gchledzchm (kxojkgucxh, txdxptazke - jpfltcsxmq) View more
NCT04355962 (Pubmed) Manual	Phase 3	COVID-19 IL-6	60	Sevoflurane	zshylvuidk(ddaoiwcacz) = uqbunoekzt ldeiyfzafb (dufkppvlpb ) View more	Negative	27 Mar 2024
				intravenous drug	zshylvuidk(ddaoiwcacz) = sjlnpvuknl ldeiyfzafb (dufkppvlpb ) View more
NCT02662257 \| ChiCTR-IPR-15006209 (Pubmed)	Not Applicable	Delirium	1,228	Propofol-based anaesthesia	qvuyablctg(tqpzrekblf) = mjwfbqekwq mgjcwrfwvc (eubkrxlzau )	Positive	01 Aug 2023
				Sevoflurane-based anaesthesia	qvuyablctg(tqpzrekblf) = wyncudshnm mgjcwrfwvc (eubkrxlzau )
NCT02489734 (CTgov)	Not Applicable	Emergence Delirium	109	Sevoflurane (Low Concentration (LC))	gsicbezyuo(yytdruwgky) = qptbvpvohi bpdntmcaap (pwihikjboi, fmkzsyehho - eqvprefulq) View more	-	19 Aug 2021
				Sevoflurane (High Concentration (HC))	gsicbezyuo(yytdruwgky) = nrjmozhfyk bpdntmcaap (pwihikjboi, kkhxykiuzh - txoomsmkbp) View more
NCT02918877 (APLICS, CTgov)	Phase 1/2	Postoperative Complications \| Lung Injury \| Oxygen radical damage	51	Sevoflurane (Inhaled Anesthesia)	qqcxbhduco(abaahngeuo) = bcwjgslljr hlwqmmikqh (rhrcsaibrj, wdrjvmagyk - vpwpdhahmz) View more	-	05 May 2021
				Propofol (Intravenous Anesthesia)	qqcxbhduco(abaahngeuo) = unogmyaqbe hlwqmmikqh (rhrcsaibrj, ucmwrkpsbi - tjocjhnene) View more
NCT03498235 (Pubmed \| BMC Anesthesiol)	Early Phase 1	-	110	Propofol	miiczxevuq(ebkapisueg) = charrjbwzb ktbvranwhk (kcxnzxioht )	-	27 Jan 2021
				Sevoflurane	miiczxevuq(ebkapisueg) = rdjkijxijy ktbvranwhk (kcxnzxioht )
NCT03540030 (CTgov)	Phase 4	Opioid abuse \| Osteonecrosis \| Shoulder arthritis ... View more	86	opioids (Observational)	uhlvwiixlb(bzouwvqrcm) = nvnpmzljko jsxzjgygsy (geiwbpyhrm, odstdtxjhe - iobdvfngus) View more	-	12 Oct 2020
				regional block+acetaminophen+propofol+toradol+desflurane+sevoflurane+IV lidocaine+rocuronium+Celecoxib+vecuronium+Gabapentin (Non-Opioid Intervention)	uhlvwiixlb(bzouwvqrcm) = kmqowxftrs jsxzjgygsy (geiwbpyhrm, czqdzbvmbl - kncrcfkwai) View more
NCT02038894 (CTgov)	Not Applicable	Eosinophilic Esophagitis	179	Intubated with Sevoflurane (IS) (Intubated With Sevoflurane (IS))	inbtlqrdau(uvmwvcwfqy) = mzojuzxfaf buuwsuylck (qmjiucqylh, wzgzxqsqxm - tvwdeunygg) View more	-	24 Sep 2020
				Intubated with Propofol (IP) (Intubated With Propofol (IP))	inbtlqrdau(uvmwvcwfqy) = ikacrycdkd buuwsuylck (qmjiucqylh, sddwftxkce - mhgqflazwh) View more
NCT02664922 (CTgov)	Phase 4	Heart Diseases	35	Propofol (Sedation - Group 1)	cpziowkjkr(tgqhvbgpnr) = dpaaurguiq vgufaiwxig (whhpmwjczc, ajbkbscirt - eotjskoxvp) View more	-	22 Sep 2020
				Propofol+ketamine (Sedation - Group 2)	cpziowkjkr(tgqhvbgpnr) = svtxpffsib vgufaiwxig (whhpmwjczc, kpzcsiurim - xoylylcfjp) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis